CHARLES CHABOUDE: Open Payments
NPI 1437679628 · JUPITER, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,236 in 148 payments from 32 companies in 2025. Trend: 2023 $2,929 · 2024 $3,086 · 2025 $3,236
Food & beverage: $3,236
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 22 | $395 |
| Dexcom, Inc. | 10 | $322 |
| Novo Nordisk Inc | 21 | $322 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 13 | $312 |
| Novartis Pharmaceuticals Corporation | 15 | $248 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $167 |
| Neurocrine BioSciences, Inc. | 1 | $118 |
| SANOFI-AVENTIS U.S. LLC | 4 | $99 |
| Sequel Med Tech, LLC | 4 | $95 |
| Corcept Therapeutics | 4 | $93 |
Products named: JARDIANCE, LEQVIO, MOUNJARO, Dexcom G6 Transmitter, Kerendia, DEXCOM G7 GSS (161), Wegovy, Ozempic.
Industry payments across FL — which companies pay providers there.
